Skip to main content

Table 1 Baseline characteristics of AF patients with and without OSA

From: Clinical characteristics and thrombotic risk of atrial fibrillation with obstructive sleep apnea: results from a multi-center atrial fibrillation registry study

 

Total

Non-OSA

OSA

p-value

 

n = 1990

n = 1920

n = 70

 

Male (n [%])

897 [45.1%]

841[43.8%]

56 [80.0%]

 < 0.01

Age (y)

71 (60–78)

71 (60–78)

66.5 (55.5–73.25)

 < 0.01

BMI (Kg/m2)

23.4 (21.3–25.7)

23.4 (21.3–25.5)

25.7 (23.4–28.4)

 < 0.01

SBP (mmHg)

130 (117–146)

130 (118–146)

127.5 (110–150)

0.86

DBP (mmHg)

80 (70–90)

80 (70–90)

80 (70–95)

0.17

Heart rate (beat/min)

97 (80–120)

97 (80–120)

98 (80–120)

0.87

Type of AF (n [%])

   

0.35

Paroxysmal

608 [30.6%]

584 [30.4%]

24 [34.3%]

 

Persistent

449 [22.6%]

430 [22.4%]

19 [27.1%]

 

Permanent

933 [46.9%]

906 [47.2%]

27 [38.6%]

 

Comorbidities

Myocardial infarction (n [%])

147 [7.4%]

141 [7.3%]

6 [8.6%]

0.70

Coronary artery disease (n [%])

835 [42.0%]

808 [42.1%]

27 [38.6%]

0.56

Congenital heart disease (n [%])

43 [2.2%]

43 [2.2%]

0 [0%]

0.21

Valvular heart disease (n [%])

333 [16.7%]

322 [16.8%]

11 [15.7%]

0.09

Heart failure (n [%])

744 [37.4%]

716 [37.3%]

28 [40.0%]

0.65

Left ventricular ejection fraction < 45% (n [%])

382 [19.2%]

364 [19.0%]

18 [25.7%]

0.16

Hypertension (n [%])

1110 [51.2%]

1064 [51.0%]

46 [55.7%]

0.09

Diabetes mellitus (n [%])

309 [15.5%]

296 [15.4%]

13 [18.6%]

0.48

Previous stroke or TIA (n [%])

374 [18.8%]

362 [18.9%]

12 [17.1%]

0.72

LVH by ECG or echo (n [%])

322 [16.2%]

305 [15.9%]

17 [24.3%]

0.17

Smoking (n [%])

425 [21.4%]

386 [20.1%]

39 [55.7%]

 < 0.01

Dementia or cognitive defects (n [%])

44 [2.2%]

43 [2.2%]

1 [1.4%]

0.65

Emphysema or COPD (n [%])

228 [11.5%]

220 [11.5%]

8 [11.4%]

0.98

Hyperthyroidism (n [%])

66 [3.3%]

65 [3.4%]

1 [1.4%]

0.66

Prior major bleeding (n [%])

48 [2.4%]

43 [2.2%]

5 [7.1%]

0.01

CHA2DS2 -VASc score

   

0.01

0–1

335

312 [16.3%]

23 [32.9%]

 

2–4

1051

1017 [53.0%]

34 [48.6%]

 

5–9

604

591 [30.78%]

13 [18.6%]

 

Medication status

Diuretic(n [%])

767 [38.5%]

740 [38.5%]

27 [38.6%]

1.00

β blocker(n [%])

874 [43.9%]

845 [44.0%]

29 [41.4%]

0.67

ACEI(n [%])

458 [23.0%]

436 [22.7%]

22 [31.4%]

0.09

ARB(n [%])

318 [16.0%]

306 [15.9%]

12 [17.1%]

0.79

Calcium channel blocker(n [%])

461[23.2%]

443 [23.1%]

18 [24.7%]

0.61

Digoxin(n [%])

609 [30.6%]

592 [30.8%]

17 [24.3%]

0.24

Aspirin(n [%])

1092 [54.9%]

1058 [55.1%]

34 [48.6%]

0.28

Clopidogrel (n [%])

138 [6.9%]

132 [6.9%]

6 [8.6%]

0.58

Statin (n [%])

476 [23.9%]

463 [24.1%]

13 [18.6%]

0.56

Warfarin (n [%])

335 [16.8%]

327 [17.0%]

8 [11.4%]

0.22

  1. ACEI angiotensin-converting enzyme inhibitors; AF atrial fibrillation; ARB angiotensin receptor blockers; BMI body mass index; COPD chronic obstructive pulmonary disease; DBP diastolic blood pressure; ECG electrocardiogram; LVH levy left ventricular hypertrophy; OSA obstructive sleep apnea; SBP systolic blood pressure
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us